Published in Vaccine Weekly, June 18th, 2003
According to recent research from Japan, "To achieve a sustained and targeted delivery of liposomes to liver nonparenchymal cells, we modified distearoyl phosphatidylcholine and cholesterol liposomes (DSPC/Chol liposomes) with a mannosylated cholesterol derivative (Man-C4-Chol), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-polyethylene glycol (PEG-DSPE).
"Each liposome formulation was adjusted to an approximate size of 70-90 nm, labelled with [H-3]cholesteryl hexadecyl ether, and injected intravenously into mice, to investigate the tissue distribution...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.